Thomas Look, MD
Affiliations: | Pediatric Oncology | Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Medical School |
Google:
"Thomas Look"Mean distance: 10.86
Children
Sign in to add trainee| Alex Kentsis | post-doc | 2008-2012 | Dana-Farber Cancer Institute, Children's Hospital Boston, Harvard Medical School |
| Justin A. Pater | post-doc | 2018-2020 | Dana-Farber Cancer Institute and Harvard Medical School |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Look T, Puca E, Bühler M, et al. (2023) Targeted delivery of tumor necrosis factor in combination with CCNU induces a T cell-dependent regression of glioblastoma. Science Translational Medicine. 15: eadf2281 |
| Meister H, Look T, Roth P, et al. (2022) Multifunctional mRNA-based CAR T cells display promising anti-tumor activity against glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Dubiella C, Pinch BJ, Koikawa K, et al. (2021) Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo. Nature Chemical Biology |
| Watanabe A, Inukai T, Kagami K, et al. (2019) Resistance of t(17;19)-acute lymphoblastic leukemia cell lines to multiagents in induction therapy. Cancer Medicine |
| Herrmann A, Lahtz C, Nagao T, et al. (2017) CTLA4 promotes Tyk2-STAT3 dependent B cell oncogenecity. Cancer Research |
| Shi H, Tao T, Kadoch C, et al. (2017) Abstract 802: Loss of function of Arid1a synergizes with MYCN in neuroblastoma pathogenesis Cancer Research. 77: 802-802 |
| Li Z, Abraham B, Berezovskaya A, et al. (2017) Abstract 5488: APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL Cancer Research. 77: 5488-5488 |
| Etchin J, Le BT, Berezovskaya A, et al. (2015) Abstract 4445: Selective inhibitor of nuclear exporter CRM1/XPO1, Selinexor (KPT-330), exhibits remarkable activity against AML leukemia-initiating cells while sparing normal hematopoietic cells Cancer Research. 75: 4445-4445 |
| Kwiatkowski N, Zhang T, Rahl PB, et al. (2014) Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 511: 616-20 |
| Roderick JE, Tesell J, Gutierrez A, et al. (2014) Abstract PR02: Targeting NOTCH1 and C-MYC in humanized models of relapsed and induction failure pediatric T-ALL Molecular Cancer Research. 12 |